Pharmacokinetic considerations for drugs that treat diarrhea-predominant irritable bowel syndrome: what’s new?

Irritable bowel syndrome (IBS), which presents a significant healthcare and socioeconomic burden, is one of the main issues in the field of therapy. Hence, it is imperative to tackle this matter by evaluating the safety and efficacy of the available treatments and determining the ideal approach for each patient.